Similarly, Yamaguchi et al. reported on 48 patients treated with first-line pembrolizumab for NSCLC with PD-L1 ≥ 50% and identified MTV as significant uni- and multivariate prognostic determinant [26]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.